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Background: Tramadol hydrochloride is available as 50 mg immediate-release (IR) and 100 mg, 
200 mg, and 300 mg sustained-release (SR) tablets. The recommended dose of tramadol is 
50–100 mg IR tablets every 4–6 hours. The tramadol SR 200 mg tablet is a better therapeutic 
option, with a reduced frequency of dosing, and improved patient compliance and quality of 
life. The present study evaluated the bioequivalence of a generic tramadol SR 200 mg tablet.
Methods: A comparative in vitro dissolution study was performed on the test and refer-
ence products, followed by two separate single-dose bioequivalence studies under fasting 
and fed conditions and one multiple-dose bioequivalence study under fasting conditions. 
These bioequivalence studies were conducted in healthy human subjects using an open-label, 
  randomized, two-treatment, two-period, two-sequence, crossover design. The oral administra-
tion of the test and reference products was done on day 1 for both the single-dose studies and 
on days 1–5 for the multiple-dose study in each study period as per the randomization code. 
Serial blood samples were collected at predefined time points in all the studies. Analysis of 
plasma concentrations of tramadol and O-desmethyltramadol (the M1 metabolite) was done by 
a   validated liquid chromatography-mass spectrometry analytical method. The standard accep-
tance criterion of bioequivalence was applied on log-transformed pharmacokinetic parameters 
for tramadol and its M1 metabolite.
Results: The ratios for geometric least-square means and 90% confidence intervals were within 
the acceptance range of 80%–125% for log-transformed primary pharmacokinetic parameters 
for tramadol and its M1 metabolite in all the three studies.
Conclusion: The test product is bioequivalent to the reference product in terms of rate and 
extent of absorption, as evident from the single-dose and multiple-dose studies. Both the treat-
ments were well tolerated.
Keywords: tramadol, multiple-dose, steady state, bioequivalence
Introduction
Tramadol hydrochloride is a centrally acting, synthetic, opioid analgesic structurally 
similar to codeine and morphine. It is available in various dosage forms for systemic 
administration. Tramadol has proven efficacy and safety in a number of acute pain-
ful conditions, including trauma, renal or biliary colic, and labor. Chronic pain of 
malignant or nonmalignant origin, particularly neuropathic pain, is also a common 
indication for tramadol.1 Tramadol is available as drops, tablets, and capsules for oral 
administration. The mean absolute bioavailability of tramadol with all oral formula-
tions is approximately 70%, irrespective of concomitant intake of food. It has a plasma 
protein binding of about 20%. Tramadol has a linear pharmacokinetic profile within 
the therapeutic dosage range. The relationship between serum concentrations and the Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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analgesic effect is dose-dependent, but varies considerably in 
individual cases. A serum concentration of 100–300 ng/mL is 
usually effective.2 The short elimination half-life of 6 hours 
necessitates dosing of patients with immediate-release (IR) 
tramadol preparations every 4–6 hours in order to maintain 
optimal levels of analgesia in chronic pain. The dose of 
tramadol is titrated upwards as necessary. The maximum 
recommended dose of tramadol is 400 mg/day.3
Successful long-term treatment of patients with painful 
conditions requires an appropriate dosage form, optimal 
dosing, and patient compliance. Sustained-release (SR) 
formulations are very helpful in achieving treatment objec-
tives. Stable serum levels without marked peak to trough 
fluctuations and reduced frequency of dosing improve patient 
compliance, patient satisfaction, and, ultimately, quality 
of life. Tramadol 100 mg, 200 mg, and 300 mg SR tablets 
are available commercially to overcome the difficulties 
associated with the frequent dosing needed for IR tramadol 
preparations.
In recent years, generic drug products have become very 
popular. Bioequivalence studies are the commonly accepted 
method to demonstrate therapeutic equivalence between two 
medicinal products. Bioequivalence can be shown either with 
a single-dose study or a multiple-dose steady-state study. 
Savings in time and cost are substantial when using bioequiv-
alence as an established surrogate marker of therapeutic 
equivalence. Ipca Laboratories Limited   (Mumbai, India) 
has developed an SR tablet containing tramadol 200 mg as a 
generic substitute for the corresponding innovator product. In 
general, a steady-state study under fasting conditions and two 
separate single-dose studies under fasting and fed conditions 
are required to demonstrate   bioequivalence for the modified-
release dosage forms. Therefore, three bioequivalence 
studies were undertaken to compare the pharmacokinetic 
properties of tramadol hydrochloride SR tablets 200 mg (Ipca 
  Laboratories Limited) and Zydol® (tramadol) SR 200 mg 
prolonged-release tablets (Grunenthal Ltd, High Wycombe, 
UK) in healthy subjects. Two studies were conducted under 
fasting and fed conditions using a single-dose approach, and 
a third study was conducted using a steady-state approach 
under fasting conditions. All of these studies were conducted 
after confirming the acceptable results of an in vitro compara-
tive dissolution study.
Materials and methods
in vitro dissolution study
A comparative in vitro dissolution study was conducted 
ahead of the in vivo bioequivalence studies. It was ensured 
that the in vitro dissolution data were acceptable as per the 
regulatory guidelines for conducting bioequivalence   studies.4 
The dissolution study was carried out on 12 units each of 
the test and reference products using the paddle method 
as per the British Pharmacopoeia monograph. The paddle 
rotation speed was maintained at 50 rotations per minute 
at 37 ± 0.5°C. The test was carried out using 900 mL of 
pH 6.8 phosphate buffer as a dissolution medium. Samples 
were drawn at hours 1, 4, 8, and 12. Each sample solution 
was analyzed by high-performance liquid chromatography 
to determine the dissolution rate. The mean dissolution 
values at each time interval were used to calculate the dif-
ference factor (f1) and similarity factor (f2) using the standard 
  mathematical equation.
in vivo bioequivalence studies
In total, 48, 60, and 54 healthy volunteers were enrolled for 
the single-dose fasting, single-dose fed, and multiple-dose 
fasting studies, respectively. The ranges for age, weight, 
and height were 19–41 years, 46–79 kg, and 149–182 cm, 
respectively. All subjects had an acceptable body mass 
index (BMI).
The studies were conducted in accordance with the 
Declaration of Helsinki, the International Conference on 
Harmonization Good Clinical Practice Guidelines, and the 
note for guidance on the investigation of bioavailability and 
bioequivalence laid down by the European Agency for the 
Evaluation of Medicinal Products.5–7 The study protocols 
were approved by the Drushti Independent Ethics Commit-
tee, Navi Mumbai, Maharashtra, India. Each subject gave 
voluntary written informed consent before participation in 
the study.
All the studies were conducted using an open-label, ran-
domized, two-treatment, two-period, two-sequence, crossover 
bioequivalence design. The duration of treatment, including 
the washout period between the two study periods, was 
12 days for both the single-dose studies and 21 days for the 
multiple-dose study.
Healthy adult male subjects were enrolled in the study. 
The sample size (number of subjects) was calculated on 
the assumption that there would not be any interaction 
between formulations and periods, the observations would 
be log normally distributed, and the variances of test and 
reference parameters would be the same. Compared with the 
single-dose fasting studies, the multiple-dose fasting study 
had more subjects, in anticipation of a higher number of 
withdrawals due to multiple exposures to the study drugs. 
Similarly, the number of subjects for the single-dose fed Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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study was the highest, considering the additional factor of 
subjects’ potential noncompliance with the “morning high-
calorie high-fat breakfast” and subsequent withdrawal from 
the study. The subjects enrolled were expected to produce a 
probability of greater than 90% for concluding bioequiva-
lence within the normal acceptance limits of 80%–125% 
for the pharmacokinetic parameters, at a consumer risk of 
5%. Subjects with significant diseases or clinically sig-
nificant abnormal findings were ruled out during screening 
by obtaining a complete medical history, performing a 
full physical examination, and laboratory investigations, 
including hematology, biochemistry,   serology, and urine 
analysis.
The subjects met all the following inclusion criteria and 
none of the exclusion criteria:
inclusion criteria
•	 Male gender, with age range 18–55 years, BMI in the 
range 18.5–24.9 kg/m2
•	 Normal baseline medical history, physical examination, 
and vital signs (blood pressure, pulse rate, respiration 
rate, and axillary temperature)
•	 Normal hematology, biochemistry, infectious disease 
screening (human immunodeficiency virus, hepatitis B, 
and hepatitis C), urinalysis, electrocardiography, and 
X-ray
•	 Willingness not to use any prescription or over the counter 
medications, including vitamins and minerals, for 14 days 
prior to and during the course of the study
•	 Nonsmoking status.
exclusion criteria
•	 Any medical or surgical condition which might signifi-
cantly interfere with the functioning of the gastrointestinal 
tract, blood-forming organs, etc
•	 History of cardiovascular, renal, hepatic, ophthalmic, 
pulmonary, neurologic, metabolic, hematologic, gastroin-
testinal, endocrine, immunologic, or psychiatric disease
•	 Participation in a clinical drug study or bioequivalence 
study 90 days prior to the present study
•	 Use of xanthine-containing beverages or food (tea, coffee, 
chocolate, and cola), grapefruit juice, and any alcoholic 
products for 48 hours prior to dosing until after the last 
sample collection in each study period
•	 Blood donation 90 days prior to commencement or during 
the study
•	 Known history of hypersensitivity to tramadol hydrochlo-
ride or related drugs
•	 Found positive on urine test for drug abuse done on the 
day of check-in for each study period
•	 History of problems with swallowing tablets.
clinical phase
All the enrolled subjects were confined for at least 12 hours 
prior to drug administration. After a fast of at least 10 hours, 
oral administration of the test and reference products was 
done on day 1 for both the single-dose studies and on 
days 1–5 for the multiple-dose study in each study period as 
per the randomization code, with 240 mL of water at ambient 
temperature. For the single-dose fed study, a high-fat high-
calorie breakfast yielding approximately 800–1000 calories 
was given to the subjects half an hour before dosing in each 
period.
A total of 22 blood samples for both the single-dose 
  studies and 26 blood samples for the multiple-dose study 
were collected from the subjects during each study period. 
Blood samples were collected predose and at 12 hours 
postdose on days 1, 2, 3, and 4 by fresh venepuncture in the 
multiple-dose study. Serial blood samples were collected 
for pharmacokinetic evaluation on day 1 for the   single-dose 
  studies and on day 5 for the multiple-dose study until 48 hours 
postdosing in each period. After collection, the blood samples 
were centrifuged at 5 ± 3°C and 3500   rotations per minute 
for 10 minutes to obtain plasma. All plasma samples were 
stored in the upright position at −20 ± 5°C until analysis of 
the samples.
The supervising medical officers or nursing staff mea-
sured vital signs under the supervision of the principal investi-
gator. Vital signs (blood pressure, pulse rate, respiratory rate, 
and temperature) were measured before check-in, predosing, 
after dosing at prescheduled times, and on discontinuation 
from the study. The subjects were monitored for any adverse 
events and/or complaints throughout the study. At the end of 
the study, poststudy evaluation, including physical exami-
nation, vital signs, 12-lead electrocardiogram, and clinical 
laboratory tests (hemogram, biochemistry, and urinalysis) 
were performed.
Bioanalytical phase
The subjects’ plasma samples were analyzed at the bioana-
lytical facility of Accutest Research Laboratories (I) Private 
Limited. Samples from periods 1 and 2 for each subject 
were analyzed together for all the studies. The investigators 
analyzing the samples did not have access to the random-
ization schedule and hence were blinded to the order of 
  administration of the study medication.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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For all the studies, the analytical method   validation 
included 0.2 mL of plasma samples and solid-phase   extraction. 
Detection was done by the liquid chromatography-mass spec-
trometry method. Imipramine was used as the internal 
  standard. The linearity range was 7.550–759.994 ng/mL and 
1.006–148.710 ng/mL for tramadol and its M1 metabolite, 
respectively. The linearity range was enough to quantify the 
expected concentration range of drug from subject’s plasma 
with the proposed dose of tramadol.
statistical analysis
All the statistical analyses were performed using SAS soft-
ware (v. 9.1; SAS Institute, Cary, NC). As per the require-
ments for single-dose and steady-state studies, the following 
parameters were calculated individually for each subject from 
their tramadol and M1 metabolite plasma concentrations: AUC 
(area under the plasma concentration-time curve in ng*hr/mL 
calculated by the linear trapezoidal method);   AUCTau (AUC 
measured throughout the dosing interval at steady state); Cmax 
(maximum plasma concentration observed, in ng/mL); Cmaxss 
(Cmax observed at steady state, in ng/mL); Cminss (minimum 
plasma concentration observed at steady state, in ng/mL); 
Cpd (predose concentration determined immediately before 
drug was given at steady state); Cavg (computed as AUCTau/Tau 
where Tau is dosing interval in hours = 24); % PTF (peak-
trough fluctuation calculated as 100 × (Cmaxss − Cminss)/Cavg); 
and Swing ([Cmaxss − Cminss]/Cminss).
Tramadol and its M1 metabolite were considered for 
establishing bioequivalence between the test and reference 
products. The pharmacokinetic parameters AUC and Cmax for 
the single-dose studies and AUCTau, Cmaxss, and Cminss for the 
multiple-dose study were taken as primary efficacy variables. 
All values below the limit of quantification were considered 
as zero for the computation of pharmacokinetic parameters 
and statistical calculations. The actual blood sampling time 
points were considered for the calculation of pharmacokinetic 
parameters.
Analysis  of  variance  (ANOVA)  was  performed 
(at α = 0. 05) on the log-transformed primary pharmacoki-
netic parameters, AUC, Cmax for the single-dose studies, 
and AUCTau, Cmaxss, and Cminss for the multiple-dose study. 
Effects of period, treatment, and sequence on primary effi-
cacy criteria were analyzed by ANOVA. Each ANOVA 
also included calculation of least-square means, adjusted 
differences between formulation means, and the standard 
error associated with these differences. The 90% confidence 
intervals for the ratio of geometric means were calculated for 
the log-transformed primary pharmacokinetic parameters. 
The confidence interval was expressed as a percentage rela-
tive to the least-square means of the reference treatments. 
Bioequivalence was to be concluded when 90% confidence 
intervals were within the acceptable range of 80%–125% for 
log-transformed primary pharmacokinetic parameters.
Results and discussion
in vitro dissolution study
Dissolution curves are shown in Figure 1. From the dissolu-
tion profiles, the difference factor (f1) of 1.39 (acceptable 
limit 0–15) and the similarity factor (f2) of 88.07   (acceptable 
limit 50–100) were obtained. A comparative in vitro 
dissolution study provides a basis for predicting the like-
lihood of   achieving a successful in vivo bioequivalence 
performance. This in vitro dissolution study showed that 
the test and reference products were comparable, indicating 
essential similarity of both the formulations.
in vivo bioequivalence studies
The subjects completing both the study periods success-
fully were considered for pharmacokinetic and statistical 
analysis of both tramadol and its M1 metabolite. Tramadol 
was rapidly absorbed after oral administration, with mean 
peak plasma levels achieved at approximately 4–5 hours 
postdose for the test as well as reference products in all 
the studies (Tables 1 and 2, Figure 2). The M1 metabolite 
was rapidly absorbed after oral administration, with mean 
peak plasma levels achieved at approximately 7–8 hours 
postdose for the test and reference products in all the studies 
(Tables 1 and 2, Figure 3). The rate and extent of absorption, 
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as evident from the Cmax and AUC0–t values for tramadol and 
its M1 metabolite, was higher for the fed state than for the 
fasting state (Table 1). In summary, the pharmacokinetic 
data obtained in all our studies were in accordance with the 
published data.1–3,8
In the multiple-dose steady-state study, it was observed 
that the mean peak-trough fluctuation for tramadol was 
151.75% for the test product and 133.55% for the   reference 
product. Corresponding values for the M1 metabolite were 
104.11% and 93.18% for the test and reference products, 
respectively (Table 2). We observed the mean peak-trough 
fluctuations in plasma tramadol concentrations to be 
significantly higher than those reported in the literature. 
Grond and Sablotzki reported a fluctuation in tramadol 
concentrations of approximately 66% with the SR tramadol 
formulation at steady state.1 Karhu and Bouchard noted this 
to be 56%–96%.8 The occurrence of high mean peak-trough 
fluctuations in our multiple-dose study could be due to insuf-
ficient frequency of drug administration. In all the published 
studies, the dosing frequency was as per the labeling of the 
innovator product. In the multiple-dose study, twice-daily 
administration of the tramadol SR tablet was an ideal way 
to reach steady state, with less fluctuation. However, once-
daily administration of tramadol probably resulted in wide 
fluctuation in this study.
Overall, the intrasubject variability observed for both the 
analytes in our studies was low. The highest variability was 
13.64%, observed for the Cminss with tramadol in our multiple-
dose study. As mentioned in the literature, wide variability in 
the pharmacokinetic parameters of tramadol, which could be 
partly due to polymorphism in cytochrome P450 isoforms, 
was not observed in the present studies.1 The subjects in our 
studies probably did not have any genetic polymorphisms 
to account for marked pharmacokinetic variability. It was 
observed that the ratios for geometric least-square means 
and 90% confidence intervals were within the acceptance 
criteria of 80%–125% for log-transformed primary pharma-
cokinetic parameters for tramadol and its M1 metabolite in 
all the studies (Table 3).
A significant period effect for the Cmax of tramadol and its 
M1 metabolite was observed in both the single-dose studies. 
However, this can be ignored because it was not coupled with 
any sequence effect. A significant treatment effect for Cmaxss 
and Cminss for tramadol and Cminss for the M1 metabolite was 
observed in the multiple-dose study. This effect might reflect 
the difference in the formulations, but it did not seem to have 
any impact on the study outcome because the confidence 
intervals for the log-transformed pharmacokinetic parameters Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Figure 3 Mean plasma concentration-time profile for M1 metabolite at steady state 
in multiple-dose fasting study.
Notes:  error  bars  indicate  standard  deviations.  Plasma  samples  obtained  after 
tramadol dosing at 96th hour (day 5) are considered for a steady-state profiling.
Abbreviations: Test, tramadol 200 mg sustained-release tablet; reference, Zydol® 
(tramadol) sustained-release 200 mg tablets.
Table 2 Mean pharmacokinetic parameters for tramadol and its M1 metabolite at steady state
Formulation Parameter Test product Reference product 
Tramadol AUcTau 
(ng*hr/mL)
cmaxss (ng/mL)
cminss (ng/mL)
Tmax (hours)
cavg (ng/mL)
PTF (%)
8368.63 ± 2410.40
 
  628.71 ± 137.52
  122.65 ± 55.44
    4.46 ± 1.09
  348.69 ± 100.43
  151.75 ± 32.52
8219.91 ± 2198.33
 
  571.96 ± 122.93
  131.59 ± 53.25
    4.90 ± 1.48
  342.50 ± 91.60
  133.55 ± 26.64
M1 metabolite AUcTau 
(ng*hr/mL)
cmaxss (ng/mL)
cminss (ng/mL)
Tmax (hours)
cavg (ng/mL)
PTF (%)
1518.03 ± 543.26
 
  94.06 ± 32.40
  29.66 ± 13.58
    6.69 ± 1.75
  63.25 ± 22.64
  104.11 ± 22.95
1528.51 ± 519.46
 
  89.70 ± 28.88
  32.06 ± 12.73
    9.55 ± 2.04
  63.69 ± 21.64
  93.18 ± 19.89
Note: Data are shown as least square mean ± standard deviation for pharmacokinetic parameters.
Abbreviations: AUcTau, area under curve at steady state; cmaxss, peak concentration at steady state; cminss, minimum concentration at steady state; Tmax, time to peak 
concentration; cavg, average concentration computed as AUcTau/24; PTF, peak trough fluctuation computed as (Cmaxss	−	cminss)/cavg.
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multiple-dose fasting study.
Notes:  error  bars  indicate  standard  deviations.  Plasma  samples  obtained  after 
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Abbreviations: Test, tramadol 200 mg sustained-release tablet; reference, Zydol® 
(tramadol) sustained release 200 mg sustained-release tablet.
fell within the acceptance range. Thus, the treatment effect 
can be ignored.
safety evaluation
In total, 48, 60, and 54 subjects were exposed to either of the 
treatments in period 1 of the single-dose fasting, single-dose 
fed, and multiple-dose fasting studies, respectively, while 
the corresponding numbers were 48, 46, and 37 in period 
2. Successful completion of the clinical phase was done by 
40, 44, and 35 subjects in the single-dose fasting, single-
dose fed, and multiple-dose fasting studies, respectively. 
The highest occurrence of adverse events was observed in 
the multiple-dose fasting study. In this study, a total of 187 
adverse events were reported, of which 103 events were 
observed in subjects given the test product and 84 events 
were observed in those given the reference product (Table 4). 
Occurrence of an adverse event was the underlying cause 
for withdrawal of 8, 14, and 16 subjects in the single-dose 
fasting, single-dose fed, and multiple-dose fasting studies, 
respectively. The poststudy laboratory evaluation did not 
reveal any clinically significant observations requiring further 
intervention in all the studies.
The majority of the adverse events were expected and 
related to the study drugs. Dizziness, pruritus, headache, and 
vomiting were the most common adverse events for both the 
study treatments, as reported by other investigators.1,9 Our 
results are consistent with the published data. The greater 
occurrence of adverse events in the multiple-dose fasting 
study could be due to the higher number of exposures of 
the subjects to the study drugs, with a relatively high dose 
of tramadol. However, we did not observe any correlation 
between the occurrence of adverse events and peaking of Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Table 3 Geometric mean ratio, intrasubject variability, and 90% confidence intervals for tramadol and its M1 metabolite in all studies
Analyte Study Parameters Percent ratio 
T/R
Percent 
intra-CV
90% CI for log-transformed data
Lower limit Upper limit
Tramadol s1 AUc0 (ng*hr/mL)
cmax (ng/mL)
97.76
111.58
9.22
11.30
94.41
106.92
101.23
116.45
s2 AUc0-t (ng*hr/mL)
cmax (ng/mL)
100.08
108.73
6.53
10.62
97.77
104.68
102.45
112.95
s3 AUcTau (ng*hr/mL)
cmaxss (ng/mL)
cminss (ng/mL)
101.28
109.88
90.62
7.43
10.14
13.64
98.28
105.48
85.78
104.37
114.47
95.74
M1 metabolite s1 AUc0-t (ng*hr/mL)
cmax (ng/mL)
98.37
106.66
7.86
10.71
95.49
102.43
101.34
111.06
s2 AUc0-t (ng*hr/mL)
cmax (ng/mL)
99.63
108.29
6.96
10.11
97.18
104.44
102.15
112.28
s3 AUcTau (ng*hr/mL)
cmaxss (ng/mL)
cminss (ng/mL)
99.23
104.42
91.29
7.75
10.12
11.82
96.17
100.23
87.04
102.39
108.77
95.75
Abbreviations: AUc0–t, area under curve; AUcTau, area under curve at steady state; cmax, peak concentration; cmaxss, peak concentration at steady state; cminss, minimum 
concentration at steady state; CV, coefficient of variation; T/R, test product/reference product; S1, single-dose fasting study; S2, single-dose fed study; S3, multiple-dose fasting 
study; CI, confidence interval.
Table 4 Occurrence of adverse events in all the studies
Adverse event Reported (n) 
Test 
product
Reference 
product
S1 S2  S3  S1  S2  S3 
Lightheadedness 00 00 01 00 00 00
giddiness 17 13 28 09 14 27
Drowsiness 00 00 01 00 00 01
headache 10 07 12 05 07 09
cold 00 01 01 02 01 00
Bradycardia 01 03 00 00 05 01
hypotension 00 02 00 00 00 02
high blood pressure 00 00 01 00 00 01
Vomiting 05 09 07 04 08 10
nausea 04 10 9 02 03 03
general abdominal pain 00 00 03 00 00 05
Burning epigastric pain 00 01 03 00 01 00
constipation 00 00 01 00 00 03
itching 03 03 19 01 00 19
Body ache 02 01 01 01 01 01
Dry skin (both feet) 00 00 01 00 00 00
Fever 01 00 04 00 02 00
shivering 00 00 01 00 00 00
Burning micturition 00 00 02 0 00 00
Difficulty in micturition 00 00 03 00 00 01
retention of urine 00 00 01 00 00 00
Bilateral shoulder pain 00 00 00 00 00 01
Bilateral knee joint pain 00 00 01 00 00 00
Pain in arm 01 00 01 00 00 00
Burning sensation in back 00 00 01 00 00 00
Backache 00 01 01 00 00 00
Total 44 51 103 24 42 84
Note: Adverse events either spontaneously reported by the subject or observed 
by the medical personnel.
Abbreviations: s1, single-dose fasting study; s2, single-dose fed study; s3, multiple-
dose fasting study.
plasma tramadol concentrations in either of the studies. All 
the adverse events were mild to moderate in severity, and 
resolved during the clinical phase. No serious adverse event 
was observed in either of the studies.
Conclusion
The in vitro dissolution study indicated suitability of the 
test product for use in the in vivo bioequivalence studies. 
All of the in vivo studies in healthy human subjects demon-
strated that the generic test tablet, tramadol hydrochloride 
SR 200 mg, is bioequivalent to the reference product, Zydol 
SR 200 mg, in terms of rate and extent of absorption. The 
highest number of adverse events and dropouts/withdrawals 
was observed in the multiple-dose fasting study. The longer 
study duration, multiple drug administration, and relatively 
high total dose of tramadol probably contributed to the find-
ings of this study. Overall, both the study treatments were 
well tolerated.
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